Lung Cancer

Dr. Edward Garon provides an overview of the most common presenting clinical features in adults with non-small cell lung cancer (NSCLC).
Dr. Edward Garon reviews how certain drugs can change the landscape for treating patients with lung cancer.
Dr. Edward Garon discusses the use of PD-1 and PD-L1 inhibitors in patients with lung cancer.
Dr. Edward Garon does not believe there is much value in utilizing PD-L1 inhibitors for pateints with ALK gene rearrangement.
Dr. Edward Garon speaks about how differences in patient populations with lung cancer can make it difficult to interpret and act on data.
Dr. Edward Garon shares an anecdote about an interesting NSCLC case from his practice.
Dr. Edward Garon explains how he discusses immunotherapies with patients.
Dr. Edward Garon describes how staff at his practice interacts with patients.
Dr. Edward Garon believes it's important to recognize that agents without efficacy are not beneficial to the patient despite low toxicity.
Toxicities related to immunotherapies approved for the treatment of patients with non–small-cell lung cancer (NSCLC) are uncommon but can be life-threatening.
Page 3 of 7
Results 21 - 30 of 70

©2018 Green Hill Healthcare Communications, LLC, an affiliate of The Lynx Group. All rights reserved.
1249 South River Road - Suite 202, Cranbury, NJ 08512